[
  {
    "title": "Charles River (CRL) Up 1.9% Since Last Earnings Report: Can It Continue?",
    "published": 1742571029
  },
  {
    "title": "Drug Development Inputs & Services Stocks Q4 In Review: Medpace (NASDAQ:MEDP) Vs Peers",
    "published": 1742547790
  },
  {
    "title": "Bell Global Equities Sold Charles River Laboratories International (CRL) Due To Its Potential For On-going Risk To Earnings",
    "published": 1740753306
  },
  {
    "title": "SGH and Charles River team up for CGMP cell banking services",
    "published": 1740501039
  },
  {
    "title": "Charles River Announces Agreement with Singapore General Hospital",
    "published": 1740488400
  },
  {
    "title": "Deciphering Charles River (CRL) International Revenue Trends",
    "published": 1740406510
  },
  {
    "title": "UFP Technologies (UFPT) Reports Q4: Everything You Need To Know Ahead Of Earnings",
    "published": 1740402225
  },
  {
    "title": "CRL Stock Up on Q4 Earnings and Revenue Beat, Margins Fall",
    "published": 1739991060
  },
  {
    "title": "Compared to Estimates, Charles River (CRL) Q4 Earnings: A Look at Key Metrics",
    "published": 1739975423
  },
  {
    "title": "Charles River beats quarterly estimates on stable demand for drug development services",
    "published": 1739970680
  },
  {
    "title": "Charles River Laboratories (CRL) Tops Q4 Earnings and Revenue Estimates",
    "published": 1739970606
  }
]